Immatics N.V. (NASDAQ: IMTX)
$7.1350
+0.0750 ( +1.93% ) 82.8K
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.